Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis

Nordic Life Science Pipeline Inc.

Status and phase: Completed; Phase 3; Phase 2

Conditions: Xerosis

Treatments: Other: standard moisturizing cream (Glaxal Base); Other: SQIN

Study type: Interventional

Funder types: Other

Identifiers

NCT02429206

SQIN-01

Details and patient eligibility

About

In the general population, xerosis is often caused by external factors such as seasonal changes. In that case, the best way to relieve dry skin is to use a standard moisturizer. However, for those suffering of mobility problems due to age or paralysis (e.g., spinal cord injury, multiple sclerosis, Parkinson's, etc), xerosis is often severe and chronic because of the multiple causes (endogenous rather than exogenous ones) underlying such mobility impairment-related skin problems. This study is a double-blind, randomized study with positive control (active comparator) to assess the safety and efficacy of SQIN with CanSATs (Co-Activation of Natural Synergistically Acting Target-receptorS) technology on dry skin in patients suffering of paralysis.

Full description

Xerosis is a medical term for dry skin. When it results in skin that is scaly and itchy, the condition is called pruritus. This occurs when natural moisture is drawn out of the skin. The skin needs moisture to protect itself. The best way to relieve dry skin normally, for those suffering of seasonal dry skin problems, is to use standard moisturizers. However, for those suffering of mobility problems due to age or paralysis (spinal cord injury, multiple sclerosis, Parkinson's, Alzheimer's, muscular dystrophy, amputation, cerebral palsy, or other comparable disorders), xerosis becomes severe and chronic because of the multiple causes (endogenous metabolic problems and dysfunctions rather than exogenous ones). SQIN with CanSATs technology is designed to act upon multiple mechanisms for enhanced protecting, moisturizing, and repairing effects. Based upon preliminary evidence, SQIN with CanSATs technology can thus elicit significantly superior effects compared with standard, commercially available moisturizers.

Enrollment: 10 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Paralyzed due to a spinal cord injury (traumatic or non-traumatic origin)
• Chronically injured (at least 3 months post-injury)
• Paraplegic or tetraplegic
• 18-75 years of age
• Men and women
• French-speaking

Exclusion criteria

• Acute or subacute stage (within 1 day and 3 months post-injury)
• Had tumor(s) (malignant or non-malignant) of the skin in the last five (5) years
• Allergic or hypersensitive to any ingredient, investigational or control product
• With psychiatric or mental disorder(s)
• Children (younger than 18 year-old) or elderly (older than 75 year-old)
• Not French-speaking

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

10 participants in 2 patient groups

Positive Control

Active Comparator group

Description:

Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.

Treatment:

Other: standard moisturizing cream (Glaxal Base)

Experimental Cream

Experimental group

Description:

Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.

Treatment:

Other: SQIN